Hyderabad, July 15 -- Aurobindo Pharma has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare.
This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only, Hyderabad-based Pharma Company said in a release here on Tuesday.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool (MPP), today announced an update to their voluntary licensing agreement to include patents relating to its use in a long-acting regimen.
The announcement follows updated guidance from the WHO recommendi...